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esponsibility of InstAbstract Cancer metastasis is the major cause of cancer morbidity and mortality, and accounts for about
90% of cancer deaths. Although cancer survival rate has been signiﬁcantly improved over the years, the
improvement is primarily due to early diagnosis and cancer growth inhibition. Limited progress has been made
in the treatment of cancer metastasis due to various factors. Current treatments for cancer metastasis are mainly
chemotherapy and radiotherapy, though the new generation anti-cancer drugs (predominantly neutralizing
antibodies for growth factors and small molecule kinase inhibitors) do have the effects on cancer metastasis in
addition to their effects on cancer growth. Cancer metastasis begins with detachment of metastatic cells from
the primary tumor, travel of the cells to different sites through blood/lymphatic vessels, settlement and growth
of the cells at a distal site. During the process, metastatic cells go through detachment, migration, invasion and
adhesion. These four essential, metastatic steps are inter-related and affected by multi-biochemical events and
parameters. Additionally, it is known that tumor microenvironment (such as extracellular matrix structure,
growth factors, chemokines, matrix metalloproteinases) plays a signiﬁcant role in cancer metastasis. The
biochemical events and parameters involved in the metastatic process and tumor microenvironment have been
targeted or can be potential targets for metastasis prevention and inhibition. This review provides an overview
of these metastasis essential steps, related biochemical factors, and targets for intervention.
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Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).5
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Cancer metastases—Challenges and opportunities 4031. Introduction
Cancer metastasis is a process in which cancer cells disseminate
from the primary tumor, settle and grow at a site other than the
primary tumor site. Most cancer deaths are caused by cancer
metastasis not the primary tumor. Cancer metastasis is the primary
cause of morbidity and mortality and responsible for about 90% of
cancer deaths1. It is now accepted that tumor distribution and
secondary site growth is not a matter of chance, but rather it is
determined by the dependence of the ʻseeds’ (the cancer cells) on
the ‘congenial soil’ (the target organ for metastasis) as proposed by
the English surgeon Stephen Paget in 18892. Until recently, cancer
research has primarily focused on the development of methods/
agents that can detect tumor at the early stage, and on agents that
inhibit tumor growth. Advances in early cancer detection and
treatment have rendered that most solid tumors are now manageable
or curable if they are diagnosed and treated before metastasis.
However, once cancers spread beyond the initial primary site, they
are usually highly incurable and fatal3. Due to a lack of under-
standing of the mechanisms that underlie the metastatic process,
limited success has been made on prevention and inhibition of
cancer metastasis.
Metastasis is a complicated event that involves multiple sequen-
tial and interrelated steps and multi-biochemical events with much
to be elucidated. Metastasis is facilitated by four essential steps:
detachment, migration, invasion and adhesion. Cancer cells ﬁrst
detach from the primary tumor, undergo migration, invasion, and
travel to different sites through blood and lymphatic vessels, then
settle (adhesion) and grow. Metastasis is regulated by various
signaling pathways and is affected by the surrounding extracellular
matrix (ECM). It is now known that metastasis genes are stress-
response genes that physiologically contribute to inﬂammation,
wound healing, and stress-induced angiogenesis4. This review is
aimed to provide an overview of the metastasis process and targetsBasem
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Figure 1 Metastatic cascade. Metastatic cells detach from the primary tum
or lymphatic vessels (intravasation), travel in the blood/or lymphatic vessels
at a distal site.for intervention with a focus on cancer cell detachment, migration,
invasion and adhesion. It is not the intent of this review to provide
an in-depth description of each parameters related to the four
essential steps and relevant intervention targets since each topic
itself can be a lengthy review. It is hoped that this review can serve
as a lead for readers who are interested in cancer metastasis and
intervention.2. Cancer metastasis
Cancer metastasis is a process of dissemination of tumor cells from a
primary tumor mass to a different site through blood vessels and
lymphatic vessels (Fig. 1). It is a complex succession of a series of
cell-biological events termed the “invasion–metastasis cascade”. The
cascade involves the development of new blood vessels (angiogen-
esis), departure of metastatic cells from the primary tumor (detach-
ment and migration), invasion through the basement membrane (BM)
and ECM surrounding the tumor, invasion of the BM supporting the
endothelium of local blood and lymphatic vessels, intravasation of the
metastatic cells into the blood and/or lymphatic vessels, adhesion of
the circulating metastatic cells to the endothelium of capillaries of the
target organ site, invasion of the cells through the endothelial cell
layer and the surrounding BM (extravasation), and ﬁnally the settling
and growth of secondary tumors at the target organ site5,6. Fig. 1
provides a brief overview of the process.
Metastatic cell dissemination requires that cells ﬁrst detach from
the primary tumor7–9. Under normal circumstances, epithelial and
endothelial cells will undergo apoptosis (programmed cell death)
when detached, a phenomenon referred to as anoikis (induction of
apoptosis caused by detachment from the ECM)10. During the
process of anoikis, both death receptor pathways and mitochondrial
pathway are activated10. This is a mechanism designed to protect
multicellular organisms from cells establishing themselves outsideent membrane (BM, specialized ECM that separates epithelial cells from
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Xiangming Guan404their correct anatomical location. Normal epithelial cells require
attachment to the ECM for survival. Metastatic cells must develop
a mechanism to adapt and survive when detached from the ECM or
in the absence of the ECM. In other words, they should develop a
mechanism to resist anoikis7,11. The resistance to anoikis together
with some other property changes of the tumor cells (such as changes
in cell-to-cell or cell-to-matrix adhesion, cell polarity, and cell
invasive and migratory property) are collectively known as the
epithelial–mesenchymal transition (EMT). EMT is a characteristic
feature of most metastatic cells11. Speciﬁcally, epithelial cells are
transformed from highly differentiated, polarized, and organized cells
into undifferentiated, isolated, and mesenchymal-like cells with
migratory and invasive properties12. Additionally, many tumor cells
also show changes in their plasticity via morphological and pheno-
typical conversions during cancer progression. These changes, in
addition to EMT, include collective amoeboid transition (CAT) and
mesenchymal to amoeboid transition (MAT)11. EMT enables cells to
increase migratory and invasive capabilities through formation of
invasive protrusions (invadopodia) while CAT and MAT enables
cells to increase migratory capability through formation of non-
invasive protrusions (lamellipodia and ﬁlopodia). Protrusions are the
extended parts formed at the leading edge of motile cells. Lamelli-
podia and ﬁlopodia are also present in normal epithelial cells while
invadopodia are mostly observed with metastatic cells (more discu-
ssion of protrusions in Section 2.1)11. Interestingly, EMT in tumor
cells is transient. Before a metastatic cell settles down and grows, it
needs to reverse its mesenchymal to a more epithelial phenotype, a
conversion known as mesenchymal–epithelial transition (MET). The
contribution of MET to cancer progression is still unclear12.
It is known that not all tumor cells are metastatic, nor are all cells
within metastatic tumors capable of metastasizing7. The four
essential steps of the cancer metastatic process (detachment,
migration, invasion and adhesion) are distinct from each other but
also interrelated. For example, cell migration involves cell detach-
ment, adhesion and invasion, while invasion involves migration and
adhesion. An understanding of these four steps and their role in
cancer metastasis helps understand the metastatic process and also
identify targets for intervention.2.1. Cancer cell adhesion, detachment, migration and invasion
2.1.1. Cell adhesion
Cell adhesion basically refers to cell attachment among cells (cell–
cell adhesion) and with cells' environment, mostly the ECM (cell–
matrix adhesion). Physiologically, cells are held within their
deﬁned boundary through tight cell–cell adhesion and cell–matrix
adhesion. Cell adhesion helps establish tight connections both
between cells and between cells and the matrix. Since cellular
motility is an essential part of cancer metastasis, and adhesion and
de-adhesion (detachment) are prerequisites for cellular motility3,
cell adhesion is critical for cancer metastasis. Adhesion is also
involved in the settling of metastatic cancer cells at a distal site.
Further, cell adhesion is not just a way to link cells or link cells
with the ECM, but it also serves as a mechanism to activate cell
proliferation and survival pathways through integrins' interactions
with downstream molecules that are essential for motile function
and survival11.
Adhesion is primarily achieved by connecting intracellular
cytoskeleton between cells (cell–cell adhesion) or connecting
cellular cytoskeleton with ECM components such as collagen,
ﬁbronectin, ﬁbrinogen, and laminin (cell–ECM adhesion) througha group of cell adhesion molecules (CAMs). CAMs are surface
glycoproteins that are typically transmembrane receptors made up of
three domains: intracellular domain, transmembrane domain, and
extracellular domain. CAMs primarily include calcium-dependent
CAMs (cadherins, integrins or selectins) and calcium-independent
CAMs [the immunoglobulin superfamily (Ig-SF) and lymphocyte
homing receptors (CD44)]13. Different types of CAMs are respon-
sible for adhesion in different types of cells. For example, E-
cadherins are responsible for epithelial cell–cell adhesion and R-
cadherins are for retinal cell adhesion11,13. CAMs are critical for cell
adhesion. A brief description of the structures and functions of
CAMs is presented below.
2.1.1.1. Integrins. Integrins are responsible for cell–ECM adhe-
sion. They are members of a glycoprotein family that form
heterodimeric receptors for ECM molecules such as ﬁbronectin
(FN), laminin (LN), collagen (Col), ﬁbrinogen, and vitronectin
(VN). They are composed of α and β subunits with non-covalent
bonds connected to each other. Both α and β subunit contains a
large extracellular domain, a transmembrane domain, and a short
intracellular domain. There are at least 19α and 8β subunits that
dimerize to yield at least 24 different integrin heterodimers with
distinct ligand binding and signaling properties11.
Cell adhesion to ECM is essentially achieved through integrin-
mediated linkage to extracellular ECM molecules and intracellular
cytoskeleton. The large extracellular domain of integrins bind
to ECM molecules while the intracellular domain is linked
to cytoskeleton through intracellular focal adhesions (FAs) as
demonstrated in Fig. 2. FAs are supramolecular complexes formed
by more than 150 different proteins, including kinases, scaffold,
and adaptor proteins, as well as actin linking proteins14. FAs also
mediate intracellular signaling pathways and are dynamic struc-
tures which assemble, disperse, and recycle during cell migra-
tion11,13. Binding of integrins to FAs and ECM molecules not only
serve as a way for cell adhesion to ECM, but also relay the forces
produced by the cytoskeleton onto ECM to generate the traction
needed for cell adhesion and migration, and to transmit signals
from the extracellular environment to the intracellular network, as
well as signals from the intracellular network to extracellular
environment. The transmission is mediated by integrin-activated
signaling molecules, such as focal adhesion kinase (FAK),
phosphatidylinositol 3-kinase (PI3K), and members of the extra-
cellular signal-regulated kinase 1 and 2/mitogen activated protein
(ERK1 and 2/MAP) kinase family to regulate cell proliferation,
migration, and apoptosis of tumor and endothelial cells (Fig. 2)10.
Therefore, integrins are not only involved in adhesion but also in
migration and invasion. They are important for cell motility due to
their ability to modulate physical interactions with ECMs and to
regulate signaling pathways that control actin cytoskeleton
dynamics and cell movement11. They also play critical roles in
regulating other biological processes, such as apoptosis, prolifera-
tion, survival, and differentiation through integrin-mediated down-
stream signaling pathways13.
During cancer differentiation and metastasis processes, up-regulation
of integrins has been linked to cancer invasiveness15–17. The subunits
α3, α5, α6, αv, β1, and β3 are expressed in metastatic cells and can be
considered as indicators for metastasis18. Integrins mediate the
synthesis of cyclins and inositol lipids as well as activation of FAK
and mitogen-activated protein kinase (MAPK)11,19. Integrins also
facilitate the metastatic process by proteolytically degrading the
basement membrane through the activation of matrix metalloprotei-
nases (MMPs)20,21. MMPs are the primary proteases responsible for
Figure 2 Illustration of cell detachment, cell–cell adhesion and cell–matrix adhesion of epithelial cells by E-cadherins and integrins respectively.
Cell detachment: cell detachment from ECM can occur through breakage of adhesion proteins at both intracellular site and extracellular site.
Cytosolic cleavage can be achieved through both mechanic forces and enzymatic cleavage while extracellular cleavage is primarily achieved
through cleavage by proteases such as MMP. Cell–matrix adhesion by integrins: cell–matrix adhesion is achieved through interaction of integrins
with intracellular cytoskeleton and extracellular ECM components. The large extracellular domain of integrin binds to ECM components such as
FN, LN, Col, ﬁbrinogen, and VN. The intracellular domain is connected to cytoskeleton through focal adhesions. Cell–cell adhesion by cadherins:
cell A and cell B are tightly linked by E-cadherins at adherent junction. The extracellular domain of the same type of cadherin (homodimers) (e.g.,
E-cadherin with E-cadherin) from the adjacent cells were tightly linked in a calcium-dependent manner. The intracellular domain of the cadherin is
connected to cytoskeleton (α-actinin, vinculin, and actin cytoskeleton) through linker proteins (α-catenin, β-catenin and p120 catenin). Cell
adhesion among other cells is achieved in a similar way except different CAMs are employed.
Cancer metastases—Challenges and opportunities 405ECM degradation during cancer metastasis. In addition, integrins
regulate tumor cell motility via Rho-A signaling cascade11. Further,
integrins promote invasion by activation of PI3K and Src which is a
proto-oncogene encoding a tyrosine kinase11. The various roles
integrins play in cancer metastasis and proliferation make integrins
an attractive target for cancer therapy.
2.1.1.2. Cadherins. Cadherins are a superfamily of transmem-
brane glycoproteins mediating homophilic (same type of cells)
cell–cell adhesion11. More than 20 members of the cadherin
molecules have been reported with cell type-speciﬁc expression
manner such as E-cadherins in epithelial cells, N-cadherins in
mesenchymal cells (such as stromal cells), VE-, P-, and
R-cadherins in vascular endothelial, placental, and retinal tissues,
respectively. Two cadherins of the same type from adjacent cells
interact in a non-covalent manner to hold two cells tightly
together11,13.
Fig. 2 employs two epithelial cells (cells A and B) to demonstrate
cell–cell adhesion with E-cadherins. These two cells are tightly
linked by the extracellular domains of two E-cadherins with each
from one of the two cells. The extracellular domain has ﬁve
repeats and calcium binding sites. The calcium ions hold the two
extracellular domains together forming the adherent junction
between the cells. The intracellular domain of E-cadherin is linkedto cytoskeleton (α-actinin, vinculin, and actin cytoskeleton)
through linker proteins (catenin complex: α-catenin, β-catenin, γ-
catenin, and p120 catenin) (Fig. 2). Formation of an intact E-
cadherin–catenin complex not only stabilizes cell–cell adhesion,
but also triggers downstream signal transduction, including Rho
GTPases, PI3K, and MAPK, as well as other pathways22.
Modiﬁcation and/or disruption of either E-cadherin or catenin
reduce cellular adhesion23, and are early-caused incidents in cancer
development. These include reduction or loss of E-cadherin by
genetic and epigenetic incidents, shedding of E-cadherin, redis-
tribution of E-cadherin to different sites in the cell, competition for
binding sites from other proteins24, or phosphorylation of catenin.
Down-regulation or decreased levels of E-cadherin is an essential
event for EMT and has been found in metastatic cancer cells.
Down-regulation or decreased levels of E-cadherin leads to loose
cell–cell connection that allows tumor cells to disseminate and
eventually metastasize. Loss of E-cadherin was also found to
correlate with epithelial morphology loss and acquisition of
metastatic potential by the carcinoma cells such as prostate, breast,
and liver25,26. Reconstitution of a functional E-cadherin adhesion
complex suppresses the invasive properties of many different
tumor cell types27–29. Interestingly, E-cadherin was found transi-
ently vanished in migrating cells, but re-expressed with the start of
cell differentiation in epithelial tissues11,30.
Xiangming Guan406In contrast to E-cadherin, N-cadherin, which is not expressed in
normal mammary epithelial cells but expressed in stromal cells, e.
g., ﬁbroblasts, has been found to be increased in prostate cancer,
breast cancer, and liver cancer. N-cadherin is one of the
mesenchymal cadherins, and involved in adhesion of cells to
stroma. Down-regulation of E-cadherin with the concomitant up-
regulation of N-cadherin reduces cancer cell adhesion ability to
epithelial cells, increases adhesion to stromal cells, and leads to
subsequent invasion of tumor cells into stroma. N-cadherin
promotes cell migration and metastasis regardless of the expres-
sion and function of E-cadherin31,32. The critical roles of N-
cadherin in tumor cell adhesion and migration make the protein an
attractive target for cancer therapy11,13.2.1.1.3. Selectins. Selectins are vascular cell adhesion molecules
(VCAMs) involved in adhesive interactions of leukocytes, plate-
lets, and endothelial cells that mediate leukocyte trafﬁcking and
hemostasis11. Selectins are involved in processes of immune
response, wound repair, inﬂammation, and hemostasis11. Reports
showed that at least one selectin (P, L, or E) is capable of binding
to any human carcinoma11, which demonstrates the potential of
selectins to mediate contacts with tumor cells within vasculature.
The absence of L-selectin, constitutively expressed on cell surfaces
of almost all leukocyte subtypes, leads to signiﬁcant attenuation of
metastasis. Inhibition or downregulation of E-selectin expression
results in attenuation of liver metastasis. On the other hand, its
upregulation redirects metastasis to the liver11,33.
2.1.1.4. The immunoglobulin superfamily (IgSF). IgSF [Ig-cell
adhesion molecules (Ig-CAM)] is a large group of cell surface
proteins that are involved in the binding, recognition, and adhesion
processes of cells, and are classiﬁed based on shared structural
features with immunoglobulins. IgSF members mediate calcium-
independent adhesion through their N-terminal Ig-like domains,
which commonly bind other Ig-like domains of the same structure
on an adjacent cell surface but may also interact with integrins and
carbohydrates34. Its C-terminal intracellular domains often interact
with cytoskeletal or adaptor proteins through which their extra-
cellular interactions can lead to signaling within the cell, enabling
these proteins to function in a range of normal biological processes
and/or tumor genesis35. They play important roles in antigen
recognition, leukocyte trafﬁcking, and formation and maintenance
of endothelial cell junctions11. A number of IgSF molecules have
been identiﬁed as biomarkers for cancer progression. For example,
melanoma CAM (MCAM) has been implicated in the progression
of melanoma, breast, and prostate cancer36–38, neuronal cell adhe-
sion molecule, member of the L1 protein family CAM (L1CAM),
neural CAM (NCAM), platelet endothelial CAM (PECAM-1),
aplysia CAM (ALCAM), and intercellular CAM-1 (ICAM-1) have
been related with metastatic cancers including melanoma, glioma,
breast, ovarian, endometrial, prostate, and colon35,39,40. Blockade of
NCAM led to susceptibility to apoptosis in murine lung tumor
cells41. Further, NCAM, MCAM, ALCAM, and L1CAM were
found up-regulated in cells following the loss of E-cadherin
expression and associated with an active, mobile state that retains
enough cell–cell junctions to allow a group of cells to move as a
unit in invading melanoma and colorectal carcinoma11,35,42,43.2.1.1.5. CD44 members. CD44 members have a single pass
transmembrane glycoprotein involved in cell–cell, cell–matrixadhesion, and cell signaling. CD44 are lymphocyte-homing receptors
and play an important role in lymphocyte homing, inﬂammation, cell
signaling, adhesion, migration, aggregation and hyaluronan (HA)
decomposition44, lymphocyte activation45, myelo- and lymphopoi-
esis45, angiogenesis46, and clearance cytokines11,47. CD44 proteins
also regulate growth, differentiation, survival, and migration, which
are all involved in tumor development and metastasis. They are
expressed in different tissues including lung, liver, central nervous
system, and pancreas48,49. CD44 family differs in extracellular
domain by addition of variable states through alternative splicing50.
The extracellular N-terminal of CD44 mediates binding to its primary
physiologic ligand HA44 and to extracellular matrix proteins such as
collagen, laminin51, ﬁbronectin52, L-selectin, and osteopontin53. The
intracellular C-terminal is attached to actin cytoskeleton54, ezrin55,
and ankyrin56, which are vital not only in cell migration but also in
signal transduction54,57. All physiological functions of CD44 are
related, in one way or another, to cell adhesion49,58. The most
important property of CD44 is its ability to bind HA, a vital factor for
the metastatic process. Therefore, inhibition of HA binding to CD44
appears to interfere with events that are critical for tumor develop-
ment like angiogenesis, apoptosis inhibition, and invasion11,59.2.1.2. Cell detachment
Cell detachment refers to a process by which cells detach mostly
from the ECM. It is the ﬁrst required step in the metastatic
cascade60. Detachment is not a simple reversal process of cell
adhesion and remains poorly understood61. Kirfel and colleagues61
describe a rear detachment during cell migration process in
embryogenesis, tissue repair and regeneration as well as cancer
and the inﬂammatory response. The paper provides some light on
the cell detachment process. Cell detachment involves both mechan-
ical forces and protease-mediated cleavage. As presented in Fig. 2,
mechanical forces generated by actomyosin-driven contraction are
believed to contribute to the dissociation of substrate adhesions at
both the cytosolic site and the extracellular site. The cytosolic
dissociation of cell–substrate adhesions can also be performed by
the calpain cysteine proteases, by phosphorylation/dephosphoryla-
tion of cytosolic adapter proteins and by posttranslational modiﬁca-
tion of integrins or adapter proteins. Extracellular dissociation of
cell–substrate adhesions can be achieved by proteolytic cleavage of
matrix constituents mediated by matrix proteases or through
shedding of matrix receptors such as integrins by speciﬁc sheddases
leaving parts of the receptors on the substrate (Fig. 2)61.
Cell detachment from the ECM in normal epithelial cells and
endothelial cells simultaneously triggers down-regulation of Bcl-xL
(an anti-apoptotic component of the mitochondrial pathway) and
up-regulation of Fas ligand (FasL) (an activator of the death
receptor pathway) within a minute resulting in anoikis10. Meta-
static cancer cells need to develop a mechanism to resist anoikis in
order to survive. Although our knowledge on ECM-detachment
and cell death has grown exponentially, how metastatic cancer
cells adapt and adopt mechanism(s) that help evade anoikis is only
beginning to be understood60. This includes the alteration of
enzyme systems in the signaling pathways that regulate anoikis,
such as small GTPases and effectors, receptor tyrosine kinases and
other kinases, NF-κB, and EMT factors60. In addition to anoikis, it
is also noted that there are multiple mechanisms (anoikis-indepen-
dent) by which normal epithelial cells would die once detached
from the ECM60. Metastatic cancer cells must overcome these
anoikis-dependent and anoikis-independent barriers in order to
survive once they lose the attachment to the ECM. To effectively
Cancer metastases—Challenges and opportunities 407eliminate metastatic cancer cells, it is suggested that both anoikis-
dependent and anoikis-independent pathways should be targeted60.
Fortunately, many of the signaling pathways are already the
targets of current FDA-approved therapeutic drugs such as
bevacizumab (Avastin) against VEGF, ramucirumab (Cyramza)
against VEGF receptor, cetuximab (Erbitux) and panitumumab
(Vectibix) against EGF receptor60. An excellent review on current
understanding of the signaling pathways that regulate anoikis
(anti-anoikis and pro-anoikis) and how the pathways are altered
to evade anoikis by cancerous cells is provided by Buchheit
and colleagues60. The review also provides an insight of anoikis-
independent cell death.2.1.3. Cell migration and invasion
The migratory and invasive abilities of cancer cells are two critical
parameters of the metastatic cascade. Metastatic cells achieve
penetration of the ECM through two different mechanisms: mesench-
ymal (ﬁbroblastoid) cell migration and amoeboid cell migration.
Mesenchymal cell migration depends on protease activities (protease-
dependent) to degrade the ECM for cell passage. Inhibition of ECM
degrading proteases, such as MMPs, is effective in inhibiting
mesenchymal cell migration. It needs to be noted that mesenchymal
cell migration is not only used by cancer cells; it is also seen with
normal untransformed cells, such as ﬁbroblasts, and endothelial and
smooth muscle cells. Amoeboid cell migration is a protease-
independent process where cells employ mechanical forces to open
a path in the ECM instead of degrading them11. The hallmarks for
amoeboid cell invasive migration are ECM loose attachment,
complete cell polarity loss, and chemotaxis capability11. Invasion of
single amoeboid cells was observed in breast cancer, lymphoma,
small cell lung and prostate carcinomas as well as in melanoma and
sarcoma11. Amoeboid cell invasion is described as the fastest
migratory phenotype in comparison with mesenchymal cell
migration11,62.
The majority of cancers originate from epithelial tissues. These tumor
cells need to remodel their tight cell–cell and cell–matrix adhesion to
gain migratory capabilities, and thus to invade adjacent tissues62. The
processes involve a dramatic reorganization of actin cytoskeleton and
concomitant formation of F-actin-rich membrane protrusions (lamelli-
podia, ﬁlopodia, podosomes, and invadopodia) at the leading edge of
motile cells. The protrusions are critical for migration and invasion
through the use of mechanic forces and protease activities. Fig. 3
demonstrates the process of an epithelial cancer cell migrating and
penetrating BM. The protrusions extend forward adhesion to their
surroundings followed by trailing end contraction11.Figure 3 Invasive migration of metastatic cancer cells. A metastatic cell r
membrane protrusions (lamellipodia, ﬁlopodia, podosomes, and invadopod
invasion through the use of mechanic forces and protease activities. They se
or the main organelle for cell locomotion (lamellipodia), or for both cell l
(invadopodia).The F-actin-rich protrusions include non-invasive protrusions
(lamellipodia and ﬁlopodia) and invasive protrusions (invadopodia).
Lamellipodia and ﬁlopodia are present in normal epithelial cells
while invadopodia are mostly observed with metastatic cells11.
Protrusions are named based on their shapes, i.e., ﬁlopodia (needle
shape), pseudopodia (round), lobopodia (cylindrical), and lamelli-
podia (ﬂat veils) and invadopodia (similar to lamellipodia but with
ECM proteolytic activity). Functionally, protrusions serve as the
cells' sensory organ (ﬁlopodia) for signals like chemoattractants and
nutrients, or the main organelle for cell locomotion (lamellipodia),
or for both cell locomotion and degradation of the ECM through the
use of proteases (invadopodia)11. Lamellipodia also interact and
attach to their environment via different adhesion molecules,
including integrins and cadherins11. Filopodia and lamellipodia
are highly interactive and interconvertible structures11.
Invadopodia appear when cell adhesion junctions and matrix
need to be concomitantly degraded. Invadopodia share an actin
ﬁlament-rich core and a multimeric protein complex surrounding
the actin core, including integrins and integrin-associated proteins
like vinculin, talin, and paxillin. They mediate ECM proteolysis
through different MMP expression11. Formation of invadopodia
involves initiation, assembly, and maturation63 and is initiated by
growth factors such as EGF (epidermal growth factor), PDGF
(platelet-derived growth factor), TGF-β (transforming growth
factor β), and/or α6β1 integrin11. Growth factor receptor signaling
activates PI3K leading to Src activation, which in turn phosphor-
ylates multiple proteins including Tks5 (tyrosine kinase substrate).
Assembly involves actin polymerization. Proteins involved in this
process include cortactin (key regulator of actin polymerization),
MENA (regulator of actin polymerization), Tks, etc. Maturation
involves Src kinase, integrins, and proteases recruiting (including
MMPs). Src kinase is a major regulator of invadopodia formation
and function63,64.
Structurally, invadopodia can be divided into three parts: proteolytic
domain, invasive domain, and adhesive domain (Fig. 3). The
proteolytic domain contains primarily proteases [MMPs, ADAM (a
disintegrin and metalloproteinase, also known as sheddases) and serine
proteases]. The invasive domain is localized inside invadopodial
protrusions into the ECM and composed of actin and actin-associate
proteins such as cortactin and MENA. The protein interactions within
this domain lead to actin polymerization that provides mechanic forces
to move the cell. The adhesive domain is localized at the edges and
anchored to the ECM. It achieves adhesive function through integrin-
mediated adhesion.
Invadopodia have been identiﬁed in numerous cancer cell lines,
including malignant melanoma, breast cancer, glioma, and headeorganizes its actin cytoskeleton and concomitantly forms F-actin-rich
ia) at the leading edge. The protrusions are critical for migration and
rve as cells' sensory organ (ﬁlopodia) for signals like chemoattractants,
ocomotion and degradation of the ECM through the use of proteases
Xiangming Guan408and neck malignancies11. It needs to be noted that invadopodia
also appear in some normal cells such as immune cells when they
have to cross tissue boundaries11.
Metastatic cancer can invade and migrate either as single cells or
as a collective group of cells11,62. While cancer cells migrating as
single cells can employ either the protease-dependent mesenchymal
migration or protease-independent amoeboid-like migration, collec-
tive cell migration employs only mesenchymal cell migration.
Single cells that leave a primary tumor at its periphery involve
the loss of epithelial polarity and the achievement of a mesenchymal
morphology through EMT. The essential characteristics of EMT are
the disruption of tight cell–cell contacts, and acquisition of a
ﬁbroblastoid spindle-shape morphology, with increased invasive-
ness and cell–stroma interactions, as well as slower rates of cell
division; altogether, these can result in the release of single cells
from a solid epithelial tumor62.
In contrast to single cell migration, cells that migrate collectively
retain their cell–cell junctions through continuous expression of
adhesion molecules. They migrate as sheets, strands, tubes or clusters
and can remain connected to the primary tumor (coordinated
invasion) or move as detached cell groups or clusters (cohort
migration). Collective cell migration requires force generation for
pulling cells from the front or pushing them from the rear. This
energy is provided by substrate binding integrins in leading cells.
Therefore the leading edge expresses β1 and β3 integrins to mediate
adhesion complexes in order to connect to ECM components such as
ﬁbronectin11. ECM attachment activates cytoskeletal adaptor proteins
such as cortactin, vinculin, paxilin, and talin. As with single invasive
cells, collectively migrating cells form membrane protrusions and
integrin-mediated focal adhesions that are connected to the actin
cytoskeleton. To penetrate the ECM, the leading cells generate an
invasion path by the use of β1 integrin-mediated focal adhesions and
local expression of MT1-MMP (MMP14) at their leading edges to
cleave the collagen ﬁbers and to orient them in tube-like structures in
which the following cell mass can migrate65,66. Collectively migrating
cells do not retract their cellular tails, but instead exert mechanical
forces, such as moving by pulling on adjacent cells that are connected
by adhesion junctions67. This clustered cohort-like cancer cell
dissemination appears to be highly efﬁcient in embolizing lymphatic
or blood vessels and in cell survival in the circulation11,62. Collective
cell migration is mainly seen for basal cell carcinomas and squamous
cell carcinomas of various origins62.2.2. Tumor microenvironment and cell motility3,11,68
It is now well understood that tumor proliferation and metastasis are
not an act-alone events of tumor cells, since tumor is required to
interact with its microenvironment [tumor microenvironment
(TME)]69–73. As presented earlier, tumor interactions with ECM
components are essential in EMT and acquisition of tumor invasive
abilities (invadopodia formation and function, proteases secretion
and function, actin polymerization, etc.). TME is closely involved
with all four essential steps (adhesion, detachment, migration, and
invasion) of the metastatic process.
Structurally, TME includes tumor's surrounding and supportive
stroma, different effectors of the immune system, blood platelets,
ﬁbroblasts, endothelial cells, proteases, cytokines, hormones and
other humoral factors. Together, these components are involved in
a complex crosstalk with tumor cells that affects growth, angio-
genesis, and metastasis69,74. The mechanisms of the interactions
between tumor cells and the TME are complex and can fall intotwo main categories: contact-dependent mechanisms that involve
cell–cell and cell–ECM adhesion molecules, and contact-
independent mechanisms that involve soluble molecules such as
growth factors, chemokines, and cytokines.
2.2.1. Chemokines
Chemokines are peptide signaling cytokines that act as a chemoat-
tractants to guide the migration of cells. They are involved in a
variety of physiological and pathological conditions including
lymph node organogenesis, inﬂammation, infection, tissue repair,
initiation, and progression of cancer11. Chemokine receptors are
expressed in a variety of cancers11. Additionally, to shift the
microenvironment to a metastasis-promoting state, cancer cells need
to either transform the resident normal stroma cells to facilitate their
growth/invasion or recruit other metastasis-promoting stromal cells
to remodel the microenvironment. Some of chemokines are shown
to have involvement in this process75.
2.2.2. Growth factors
In addition to cell growth stimulation and cell proliferation, many
growth factors, such as VEGF (vascular endothelial growth factor),
FGF (ﬁbroblast growth factor), PDGF, CTGF (connective tissue
growth factor), HGF (hepatocyte growth factor), and EGF, are fully
involved in cell migration, angiogenesis, lymphangiogenesis, EMT,
and regulation of cell adhesion, etc76. For example, activation of
ErbBs ligands, a family member of EGF-related peptides, and
overexpression of EGFR (EGF receptor) signiﬁcantly increase tumor
cell motility and intravasation77. In addition, HGF/Met signaling was
found to be involved in a variety of cellular processes including cell
motility. HGF and Met have also been indicated in the modulation of
actin cytoskeleton and MMPs secretion11,78. CTGF/CCN2 family
member 2 (CCN2) has been reported to be associated with
extracellular matrix remodeling, angiogenesis, chemotaxis, cell adhe-
sion and migration, and expression of MMPs. Overexpression of
CCN2/CTGF was associated with invasive potential of lung and
breast cancers. Neutralizing CCN2/CTGF with an antibody attenu-
ated metastasis of pancreatic cancer79. Inhibition of CCN2/CTGF
expression could lead to inhibition of migration79. Growth factor
signaling pathways have been effective targets for cancer growth
inhibition and metastasis inhibition76.
2.2.3. Cancer-associated ﬁbroblasts (CAFs)
CAFs are distinctive cell types recognized as constituting part of
the carcinoma and increasingly implicated as functional partici-
pants in tumor formation and progression12. CAFs have been
shown to enhance primary tumor growth and promote malignancy
via HGF secretion80. Moreover, ﬁbroblast HGF expression can be
induced by tumor cells due to cytokine secretion such as IL-181. In
a similar manner, CAFs have been found to express highly stromal
cell-derived factor-1 (SDF-1), implicating the tumor growth-
promoting role of ﬁbroblasts, and to provide chemotactic signals
for cancer cell invasion and migration82,83. CAF signaling can be a
target for cancer treatment11.
2.2.4. Tumor-associated macrophages (TAMs)
The macrophages within tumor are referred to as tumor-associated
macrophages. Upon activation by cancer cells, the TAMs can
release a vast diversity of growth factors, proteolytic enzymes,
cytokines, and inﬂammatory mediators. TAMs promote cancer
metastasis through several mechanisms that include tumor angio-
genesis, tumor growth, and tumor cell migration and invasion.
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pathways in metastasis11.2.2.5. Proteases and MMPs
Proteases are enzymes that cleave protein peptide bonds. At least
500–600 proteases have been identiﬁed that cleave peptide bonds
through different catalytic mechanisms11. Proteases employ serine,
cysteine, and threonine residues or a water molecule as a nucleo-
phile in the active site. They serve various different functions such
as activation and inactivation of enzymes, activation of growth
factors, gene expression, cell differentiation, cell cycle progression,
cell proliferation, and cell death. The link between proteases and
cancer was identiﬁed in 1946 by Fisher who proposed that tumor-
associated proteolytic activity could be responsible for the degrada-
tion of the cell matrix and tumor cell invasion into the surrounding
normal tissues. The major enzymes responsible for matrix degrada-
tion are matrix metalloproteases (MMPs). In addition to MMPs,
serine proteases are also involved in matrix degradation11,84.
MMPs are a family of zinc-dependent endopeptidases capable
of cleaving the basement membrane and all ECM constituents.
MMPs are produced by different cells including endothelial cells,
leukocytes, macrophages, ﬁbroblasts, and tumor cells11. They are
synthesized as inactive enzymes and activated outside the cell by
other MMPs or serine proteinases11. MMPs consist of at least 26
proteases and are subdivided into four groups: collagenases,
gelatinases, stromelysins, and matrilysins11.
MMPs' role in metastasis is complex. In addition to cleavage of
ECM, their targets also involve growth factor receptors, cytokines,
chemokines, CAMs, apoptotic ligands, and angiogenic factors that
contribute to all stages of tumor progression such as proliferation,
adhesion, migration, angiogenesis, apoptosis, and evasion of the
immune system11.
The serine proteases (SPs) are one of the largest preserved
multigene proteases with well-described roles in the differentFigure 4 Agents that revprocesses including blood coagulation, wound healing, digestion,
immune response, tumor growth, invasion, and metastasis85,86. uPA
(urokinase plasminogen activator) was ﬁrst demonstrated by Duffy
et al.87 and is a cell surface serine protease that is involved in ECM
degradation, cancer invasion, and metastasis11. It has been demon-
strated that the uPA system is able to induce human cancer cell
proliferation by the proteolytic activation of factors such as HGF,
TGF-β, and basic ﬁbroblast growth factor (bFGF) or through uPA
receptor interaction with integrins and following activation of the
FAK and EGF tyrosine kinase receptors11.3. Targets for intervention
Because metastatic cancer shares a number of common bio-
chemical parameters and steps, targeting these parameters and
steps has unique advantages in controlling metastasis as com-
pared to targeting the parameters that control cancer growth; the
latter is the base of most current chemotherapeutic agents.
Various steps related to EMT, anoikis, cell motility, and tumor
microenvironment have been targeted. The biochemical para-
meters and steps involved in motility are especially metastatic
unique. The intervention methods employed include the use of
miRNA, monoclonal antibodies, and small molecules4.
3.1. Targeting EMT and anoikis
Blocking EMT and/or reversing anoikis-resistance are rational
approaches to inhibit cancer proliferation and metastasis10. Saka-
moto and Kyprianou10 provide an excellent review for the current
understanding of molecular signaling networks involved in anoikis
and the development of agents that reverse anoikis-resistance. The
review also provides the current status of various classes of agents
developed. These agents include quinazoline-based anoikis indu-
cers as well as inhibitors of PPARγ, TrkB, and SRC (Fig. 4)10.erse anoikis-resistance.
Xiangming Guan4103.1.1. The quinazoline-based anoikis inducers
The quinazoline-based anoikis inducers started with the ﬁnding
that two quinazoline α1-adrenoceptor antagonists [doxazosin and
terazosin (Fig. 4)] exhibit signiﬁcant anti-tumor activity through
induction of receptor-mediated apoptosis involving death-inducing
signaling complex (DISC) formation/caspase-8 activation and
inhibition of Akt activation88–90. Structural modiﬁcation of these
two lead compounds led to more potent analogs DZ-3 and DZ-50
(Fig. 4) that showed effective induction of anoikis and inhibition
of cell migration and adhesion of prostate cancer cells10.
3.1.2. PPARγ inhibitor
Peroxisome proliferator-activated receptor gamma (PPAR-γ)
belongs to the nuclear hormone receptor family. PPARγ has
recently become a putative therapeutic cancer target in a variety
of epithelial cell tumors91. Inhibition of PPAR-γ by T0070907
(Fig. 4) caused cell death by reducing adhesion and inducing
anoikis91.
3.1.3. TrkB inhibitor
The Neurotrophic tyrosine kinase receptor (TrkB) has been found
to be a potent anoikis suppressor. TrkB overexpression in
nonmalignant cells promotes the formation of lung and heart
metastases. Consistently, overexpression of TrkB is frequently
found in many aggressive gastric and prostate carcinomas11,92–94
Trk inhibitor CEP-751 (Fig. 4) was demonstrated to exhibit
antitumor activity95. Later, a soluble lysinyl-β-alanyl ester of
CEP-751 named CEP-2563 dihydrochloride (Fig. 4) was also
reported and underwent clinical trials96.
3.1.4. SRC inhibitor
The Src kinases are currently being investigated as valuable
therapeutic targets for cancer treatment. Several SRC inhibitors
are now in clinical development, including dasatinib, bosutinib,
and saracatinib. Among these SRC inhibitors, dasatinib (Fig. 4) is
the most clinically studied SRC inhibitor97. In orthotopic nude
mouse models, dasatinib treatment effectively inhibits both tumor
growth and development of lymph node metastases in both
androgen-sensitive and androgen-resistant prostate cancer98. Dasa-
tinib suppresses cell adhesion, migration, and invasion of prostate
cancer cells by blocking the kinase activities of the SFKs, Lyn,
and Src98.
3.1.5. Metastatic-related endogenous miRNAs
Metastatic-related endogenous miRNAs have been found to play a
signiﬁcant role in various steps of the metastatic cascade.
Depending on their roles, metastatic-related miRNAs are referred
to as pro-metastatic or anti-metastatic. Potentially this can be a
basis to develop therapeutic intervention for the prevention and
cure of metastatic cancer through either inhibiting pro-metastatic
or by over-expressing anti-metastatic miRNAs. Efforts have been
made to develop anti-miRNA oligonucleotides with different
chemical modiﬁcations to affect EMT and anoikis12. Profumo
and Gandellini provide a good overview of miRNA-based
therapy12.
3.2. Targeting cell motility
Cell motility plays an essential role in cancer cell detachment,
migration, invasion, and adhesion. Interference of cell motility
becomes an appealing approach in developing agents for thetreatment of metastatic cancer3. The approaches primarily include
inference of interactions of CAMs with their targets and related
signaling pathways, and interference of the formation and function
of invadopodia.3.2.1. Interference of CAMs' interaction with their targets and
related signaling pathways
3.2.1.1. N-cadherin inhibitors. The critical roles of N-cadherin in
tumor cell motility make N-cadherin an attractive target for the
inhibition of cancer metastasis. The ﬁrst synthetic N-cadherin
antagonist, a linear decapeptide (N-Ac-LRAHAVDVNGNH2),
was described in 1990 by Blaschuk and co-workers99. Since then,
several types of N-cadherin antagonists have been reported. They
include synthetic linear peptides, synthetic cyclic peptides, and
non-peptidyl peptidomimetics designed based on the cell adhesion
recognition (CAR) sequence His-Ala-Val100. Another type of
antagonist is a synthetic linear peptide that harbors a Trp residue
in the second position from the N-terminus (similar to N-
cadherin)13. One of these peptides is His-Ser-Trp-Thr-Leu-Tyr-
Thr-Pro-Ser-Gly-Gln-Ser-Lys-NH2. The peptide inhibits endothe-
lial cell tube formation in vitro indicating that it has anti-
angiogenic properties13. Additionally, two monoclonal antibodies
against the extracellular domain of N-cadherin were reported to
inhibit the invasiveness and proliferation of N-cadherin expressing
PC3 human prostate carcinoma cells in vitro13. Among all these
inhibitors, the most studied cyclic peptide is N-Ac-Cys-His-Ala-
Val-NH2 (designated ADH-1) (Fig. 5). ADH1 (Exherin) was the
ﬁrst N-cadherin antagonist that entered clinical trials. ADH1
selectively and competitively binds to N-cadherin and blocks its
function. ADH1 has been tested in a phase II clinical trial as a
monotherapy and in various phase I combination trials with
cytotoxic drugs such as docetaxel, carboplatin, capecitabine, and
melphalan13.
3.2.1.2. Integrin antagonists. Integrins play key roles in cell
motility because of their ability to mediate physical interactions
with the ECM, cytoskeleton, and signaling pathways that control
actin cytoskeleton dynamics and cell movement11. In addition,
integrins also play roles in EMT and anoikis through signaling
pathways. The α5β1, αvβ3 and αvβ5 integrins are widely
expressed in different cancers and recognize the tripeptide Arg-
Gly-Asp (RGD) motif present in several ECM proteins101. Integrin
antagonists have been found effective in controlling cell prolifera-
tion and metastasis11,13,102.
The ﬁrst small molecule integrin antagonist developed was
cilengitide (EMD 121974) [Cyclo-L-Arg-Gly-L-Asp-D-Phe-N
(Me) L-Val]103 which is a cyclic peptide belonging to the RGD-
peptide family. Cilengitide binds to the integrin β chain and
prevents the interaction of integrins with their endogenous ECM
ligands. Cilengitide is effective in treating lung cancer, prostate
cancer, melanoma, glioblastoma, leukemia, brain and CNS tumors,
breast cancer, and squamous cell cancer and has undergone Phase
I and II clinical trials11.
1a-RGD (Fig. 5) is an RGD-like integrin antagonist containing a
bicyclic pseudopentapeptide that binds αvβ3, αvβ5 and α5β1
integrins with in vitro preferential afﬁnity towards αvβ3. 1a-RGD
was demonstrated to decrease cell migration and attachment,
disassemble the actin cytoskeleton, reduce FAK phosphorylation,
decrease the expression of target integrins at transcriptional level and
induce anoikis in human U251 and U373 glioblastoma cell lines that
express αvβ3 and αvβ5 and α5β1 integrins101.
Figure 5 Structures of CAM inhibitors.
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NH2), was designed based on a sequence of ﬁbronectin (Pro-His-
Ser-Arg-Asn) through replacement of Arg with Cys. ATN-161
interferes binding of α5β1 integrin with this region of ﬁbronectin
to inhibit cancer growth and metastasis104–106 and has undergone
phase I trials11,13.
In addition to these small molecule antagonists, monoclonal
antibodies against integrins have also been reported. They include
CNTO95, etaracizumab (MEDI-522), and volociximab. These
antibodies have undergone various phases of clinical trials11,13.
3.2.1.3. Selectin inhibitors. Selectins have been implicated in
mediating contacts with tumor cells within vasculature. Inhibition
or downregulation of E-selectin expression results in attenuation of
liver metastasis. In contrast, its upregulation redirects metastasis to
the liver33. Heparin is shown to inhibit P-selectin-mediated interac-
tions of platelets with cancer cell ligands in mice metastatic
states107. Thus, compounds having both heparanase and selectin
inhibition properties are promising for cancer therapy. Borsig
et al.108 reported the novel semisynthetic sulfated trimannose CC-
linked dimers (STMCs) (Fig. 5) with inhibitory activity for
heparanase and selectin. This STMC hexa-saccharide is an in vivo
effective inhibitor of P-selectin with antimetastasis activities in
animal models11,108.
3.2.1.4. CD44 antagonists. The CD44 transmembrane glycopro-
tein family, a hyaluronan receptor, mediates cellular responses to
the microenvironment through binding of hyaluronic acid (HA)
and other proteins of the ECM. These interactions start intracel-
lular signaling cascades that foster tumor growth, survival and
spread109. CD 44 is associated with aggressive tumor growth,
proliferation, and metastasis, and has been a target for metastasis
treatment11,59. In normal physiology, this receptor has a crucial
role in cell adhesion, inﬂammation, and repair processes110.
Systemic use of antibodies against CD44v epitope decreased
pancreatic adenocarcinoma metastasis11. Anti-CD44 antibody-
targeting radiolabels or anticancer chemotherapeutics have been
adopted in some patients11. Immunotoxin, a humanized antibody
complexed with a cytotoxic drug mertansine against CD44v6, has
entered into Phase 1 clinical trials and was reported to improve the
conditions in 30 incurable squamous cell carcinoma patients11. Liu
et al.11 showed that miRNA-34a was a negative CD44þ prostatecancer cell regulator. It enforced expression of miRNA-34a in
CD44þ prostate cancer cells and inhibited clonogenic expansion,
tumor regeneration, and metastasis.3.2.2. Interference with the formation and function of
invadopodia
Unlike other actin-based protrusions such as lamellipodia and
ﬁlopodia that are present in normal cells, invadopodia are uniquely
present in invasive cancer cells and considered as the transformed
version of podosomes which are present in highly invasive normal
cells such as macrophages, osteoclasts and dendritic cells64. The
main function of invadopodia in tumors is to promote matrix
degradation and tumor invasion. Invadopodia play critical roles
during three steps of the metastatic process: invasion into the
surrounding stroma, intravasation into the vasculature and extra-
vasation64. Invadopodia has emerged as an appealing target for
metastasis prevention and inhibition111.
Intervention of invadopodia can be achieved by impacting the
formation, structure and function of invadopodia. For example,
since formation of invadopodia involves growth factors, growth
factor inhibitors affect invadopodia formation. Suppressing inva-
dopodia formation, structure, and function by inhibiting Src,
Twist1 or Tks5 has been convincingly shown to inhibit tumor
metastasis in various tumor models64. MMP inhibition also
inhibits invadopodia formation112. Blocking MMP activity by
inhibitors, antibodies, or siRNA impairs invadopodia function and
matrix degradation63,112.
Since invadopodia are only involved in metastasis not cell
proliferation, it is suggested that invadopadia inhibitors should be
used in combination with an inhibitor of cell proliferation to
prevent metastasis as well as to inhibit cancer growth.3.3. Targeting tumor microenvironment (TME)
As described earlier, TME plays essential roles in the metastasis
cascade. Extensive research efforts have been made to interfere
with communication of tumors with TME to achieve the inhibition
of cancer growth and metastasis. Various TME components and
signaling pathways that impact cancer metastasis have been
targeted. They include inhibition of proteases, interference with
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rence with hypoxia processes, and remodeling of ECM11,73,113.3.3.1. Inhibition of growth factor signaling
As presented earlier, growth factor signaling is not only involved
in cancer proliferation, but also essential in EMT and acquisition
of a tumor invasive abilities. Various inhibitors against VEGF,
FGF, PDGF, and EGFR signaling have been developed. These
inhibitors include small molecules (Fig. 6) and monoclonal
antibodies such as bevacizumab against VEGF, ramucirumab
against VEGF receptor, and cetuximab and panitumumab against
EGF receptor73.3.3.2. Inhibition of proteases
A hallmark of tumor cell invasion is upregulation of proteolytic
enzymes, especially MMPs3. Inhibition of MMPs was considered
to be a very promising approach and was studied in a variety of
clinical trials as therapy for various types of cancers. Unfortu-
nately, those trials were largely unsuccessful3. The disappointing
outcomes are probably caused by various factors that include the
development of drug resistance by the tumor cells, lack of
sufﬁcient speciﬁcity of the inhibitors, and changes in the cancer
cell migration and invasion mechanism from proteolysis-
dependent migration to proteolysis-independent migration
(amoeboid cell migration through mesenchymal-amoeboid tran-
sition)11,112. It has been suggested that the combination of a
MMP inhibitor with other chemotherapeutic agents would
probably yield a better therapeutic outcome. Presented in Fig. 7
are representative small molecule MMP inhibitors, which are
grouped chemically as hydroxamates, thiol-based analogs, pyr-
imidine-2,4,6-triones and others4,11. Additionally, monoclonal
antibodies against MMPs have also been reported4,11.
uPA is a serine proteases involved in ECM degradation,
cancer growth and metastasis. A number of small molecule
uPA inhibitors have been reported. They include A6 [a capped,
eight L-amino acid peptide (Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-
Glu-NH2) derived from the biologically active connecting pep-
tide domain of the serine protease], Suramin, WX-UK1, and WX-
671 (Fig. 8)11.Figure 6 Chemical structures of small molecules3.3.3. Interference with inﬂammation11,73,114,115
It is well accepted that inﬂammation is closely associated with
cancer growth and metastasis116. Inﬂammation can impact cancer by
providing bioactive molecules from cells inﬁltrating the tumor
microenvironment. These bioactive molecules include cytokines,
growth factors, chemokines, cell survival signals to avoid apoptosis,
proangiogenic factors, and ECM modifying enzymes116. Interfer-
ence with the function of these bioactive molecules has been
demonstrated to be effective in the inhibition of`cancer growth and/
or metastasis. Fig. 9 presents representative small molecules that
interfere with the inﬂammation process. In addition, neutralizing
antibodies against CCL2 [chemokine, (C–C motif) ligand 2], CSF-1
(chemokine, colony stimulating factor-1), IL-6 (Interleukin-6, cyto-
kine), IL-6 receptor, TNF, TGF-β have also been reported73. IL-6
plays a key role in promoting proliferation and inhibition of
apoptosis by binding to its receptor (IL-6Rα) and co-receptor
gp130 (glycoprotein 130). The binding activates the JAK/STAT
signaling pathway of the Janus kinases (JAK) and signal transducers
and activators of transcription (STATs) STAT1 and STAT372.
STATs belong to a family of transcription factors closely associated
with the tumorigenic processes. Several studies have highlighted the
effect of the IL-6/JAK/STAT signaling pathway on cancer initiation
and progression72,73,116. Current attempts to target the IL-6/JAK-
STAT3 pathway include the clinical use of IL-6 and IL-6 receptor
blocking antibodies, speciﬁc STAT3 inhibitors and JAK
inhibitors72.
The IκB kinase (IKK) complex is the key enzyme in activation
of the NF-κB pathway116. NF-κB is a transcription factor that
controls the expression of a number of important genes for
mediating immune and inﬂammatory responses. IKK inhibitor
PS-1145 (Fig. 9) has been found effective in treating lymphoma73.3.3.4. Inhibition of integrin signaling4,11,116
Inhibition of integrin signaling has been presented in the earlier
section and will not be discussed further..3.3.5. Interfering with hypoxia process
Hypoxia is a characteristic microenvironment in the majority of
solid tumors117. Tumor hypoxia is a result of rapid tumor cellthat inhibit growth factor signaling pathways.
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Figure 7 Structures of representative MMP inhibitors.
Figure 8 Structures of representative uPA inhibitors.
Cancer metastases—Challenges and opportunities 413proliferation that exceeds the development of the tumor's blood
supply. Hypoxia-inducible factors (HIFs) are transcription factors
that respond to a decrease in oxygen in the cellular environment.Activation of HIF-l (hypoxia-inducible factor 1) in cancer can
increase the transcription of many genes involved in glucose
metabolism, apoptosis resistance, invasion, metastasis and
Figure 9 Chemical structures of representative compounds that interfere with the inﬂammation process. CCL2: chemokine (C–C motif) ligand 2;
CSF-1: chemokine colonystimulating factor-1; JAK: Janus kinases; IKK: The IκB kinase (IKK) complex; TGF-β: transforming Growth Factor β;
CXCR2: chemokine receptor type 2; CCR3: chemokine receptor; COX2: cyclooxygenase 2.
Xiangming Guan414angiogenesis. HIF-l has been considered to be an attractive target for
the development of novel cancer therapeutics. Fig. 10 presents some
selected inhibitors of HIF-1118.
3.3.6. Remodeling of ECM
Remodeling of the ECM has also been explored for metastasis
inhibition113. Hyaluronan [hyaluronic acid (HA) or hyaluronate] is
one of the chief components of the ECM and plays a critical role in
tumor cell adhesion and migration. Hyaluronidases are a family of
enzymes that degrade hyaluronan. There is compelling evidence
that the administration of exogenous hyaluronidase can impose
signiﬁcant anticancer activity in HA-overexpressing tumors113.
Recombinant human hyaluronidase, halozyme (Hylenex™) also
known as rHuPH20, is an FDA-approved enzyme that can
reversibly degrade HA, lower the viscosity of hyaluronan, increasetissue permeability, and hence enhance the absorption and disper-
sion of chemotherapeutic agents. Its PEGylated form (PEGPH20),
which exhibits longer survival time in vivo, has recently been
introduced into clinical trials113.
Heparan sulfate proteoglycans (HSPGs) are an integral and
dynamic part of normal tissue architecture at the cell surface and
within the ECM. Sulfatases and heparanase are key enzymes for
the degradation of HSPGs. Recently, these enzymes have been
reported to be required in tumor initiation and progress. Inhibitors
of heparanase, mostly heparan sulfate mimetics, have been found
to be effective as anti-metastatic agents and some of them have
undergone various stages of clinical trials119. While heparanase
inhibitors exhibit promising potential for cancer treatment, the
effect on cancer growth and metastasis of sulfatase inhibitors is
less certain119.
Figure 10 Chemical structures of representative compounds that interfere with HIF-1 function118.
Figure 11 Chemical structure of LY2157299.
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CAFs are distinctive cell types recognized as constituting part of the
carcinoma and increasingly implicated as functional participants in
tumor formation and progression12. CAFs have shown to enhance
primary tumor growth and promote malignancy via HGF secre-
tion11. Moreover, ﬁbroblast HGF expression can be induced by
tumor cells due to cytokine secretion such as IL-111. In a similar
manner, CAFs have been found to highly express SDF-1, implicat-
ing the tumor growth-promoting role of ﬁbroblasts, and provide
chemotactic signals for cancer cell invasion and migration11. CAF
signaling can be a target for cancer treatment11. Inhibitors of CAFs
include those that inhibit growth factor signaling such as TGF-β,
PDGFR, VEGF, VEGFR, HGF/MET, and IGF-1R11. They also
include monoclonal antibody (Avastin/bevacizumab), antisense
oligo (AP12009/trabedersen), fusion protein (Aﬂibercept/VEGF-
TRAP) and small molecule inhibitor such as LY2157299
(Fig. 11), a receptor kinase inhibitor targeting cancer-associated
ﬁbroblasts11.4. Summary
Despite extensive research efforts on cancer treatment, overall
survival has not been improved signiﬁcantly in metastasis cancer
patients. This is primarily due to the reason that the predominant
cancer treatment focuses on inhibition of cancer growth, with little
emphasis on metastasis. Limited success has been made in terms
of treating cancer metastasis, though the current new generation
anti-cancer drugs (predominantly neutralizing antibodies for
growth factors and small molecule kinase inhibitors) do haveeffects on cancer metastasis in addition to their effects on cancer
growth4.
The rapid advance in our understanding of cancer metastasis at
molecular and cellular levers as well as signaling pathways in the
past 30 years provides numerous potential targets for the inter-
vention of cancer metastasis. This is especially true in terms of
intervention with biochemical processes and signaling pathways
involved in cell detachment, migration, invasion, adhesion, and
cancer cell communication with tumor microenvironment. In view
of the complexity of cancer metastatic cascade such as anoikis-
dependent vs. anoikis-independent pathways, mesenchymal cell
migration (protease-dependent) vs. amoeboid cell migration (pro-
tease-independent), a combination that inhibits multiple elements
in the cancer metastasis cascade might be needed to produce
effective metastasis inhibition. Further, simultaneous inhibition of
both cancer growth and metastasis will likely be required to
produce clinically effective therapeutic outcomes.References
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